Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment

References

• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAtlas: Multiple Sclerosis Resources in the World 2008GenevaWHO2008 Available from: http://whqlibdoc.who.int/publications/2008/9789241563758_eng.pdfAccessed May 12, 2014
   Google Scholar
• EllwardtEZippFMolecular mechanisms linking neuroinflammation and neurodegeneration in MSExp Neurol Epub2014214
   Web of Science ®Google Scholar
• NylanderAHaflerDAMultiple sclerosisJ Clin Invest201212241180118822466660
   PubMed Web of Science ®Google Scholar
• NoseworthyJHLucchinettiCRodriguezMWeinshenkerBGMultiple sclerosisN Engl J Med20003431393895211006371
   PubMed Web of Science ®Google Scholar
• StüveOOksenbergJMultiple sclerosis overview2010 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20301492Accessed July 3, 2014
   Google Scholar
• ScottLJGlatiramer acetate: a review of its use in patients with relapsing–remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosisCNS Drugs2013271197198824129744
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
   PubMed Web of Science ®Google Scholar
• MartaMGiovannoniGDisease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizonCNS Neurol Disord Drug Targets201211561062322583439
   PubMed Web of Science ®Google Scholar
• HalpernRAgarwalSDembekCBortonLLopez-BresnahanMComparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisPatient Prefer Adherence20115738421423591
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• WingerchukDMCarterJLMultiple sclerosis: current and emerging disease-modifying therapies and treatment strategiesMayo Clin Proc201489222524024485135
   PubMed Web of Science ®Google Scholar
• JohnsonKPRisks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisTher Clin Risk Manag2010615317220421914
   PubMed Web of Science ®Google Scholar
• LalivePHNeuhausOBenkhouchaMGlatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of actionCNS Drugs201125540141421476611
   PubMed Web of Science ®Google Scholar
• JalilianBEinarssonHBVorup-JensenTGlatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?Int J Mol Sci20121311145791460523203082
   PubMed Web of Science ®Google Scholar
• BlanchetteFNeuhausOGlatiramer acetate: evidence for a dual mechanism of actionJ Neurol2008255Suppl 1263618317674
   PubMed Web of Science ®Google Scholar
• ArnonRAharoniRNeurogenesis and neuroprotection in the CNS-fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disordersMol Neurobiol200736324525317955199
   PubMed Web of Science ®Google Scholar
• TeitelbaumDFridkis-HareliMArnonRSelaMCopolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responsesJ Neuroimmunol19966422092178632064
   PubMed Web of Science ®Google Scholar
• ComiGMartinelliVRodegherMEffect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialLancet200937497001503151119815268
   PubMed Web of Science ®Google Scholar
• AharoniRThe mechanism of action of glatiramer acetate in multiple sclerosis and beyondAutoimmun Rev201312554355323051633
   PubMed Web of Science ®Google Scholar
• CarterNJKeatingGMGlatiramer acetate: a review of its use in relapsing–remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosisDrugs201070121545157720687620
   PubMed Web of Science ®Google Scholar
• SimpsonDNobleSPerryCGlatiramer acetate: a review of its use in relapsing–remitting multiple sclerosisCNS Drugs20021612825850 Review12421116
   PubMed Web of Science ®Google Scholar
• YongVWDifferential mechanisms of action of interferon-beta and glatiramer acetate in MSNeurology200259680280812349849
   PubMed Web of Science ®Google Scholar
• ChiariniMSottiniAGhidiniCRenewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetateMult Scler201016221822720007428
   PubMed Web of Science ®Google Scholar
• RatchfordJNEndresCJHammoudDADecreased microglial activation in MS patients treated with glatiramer acetateJ Neurol201225961199120522160466
   PubMed Web of Science ®Google Scholar
• SellebjergFHesseDLimborgSDendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosisMult Scler201319217918722653658
   PubMed Web of Science ®Google Scholar
• PulRMorbiducciFŠkuljecJGlatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patientsPLoS One2012712e5186723284793
   PubMed Web of Science ®Google Scholar
• BurgerDMolnarfiNWeberMSGlatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosisProc Natl Acad Sci U S A2009106114355435919255448
   PubMed Web of Science ®Google Scholar
• StasiolekMBayasAKruseNImpaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosisBrain2006129Pt 51293130516513684
   PubMed Web of Science ®Google Scholar
• HøglundRAHolmøyTHarboHFMaghazachiAAA one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA)PLoS One201384e6223723614042
   PubMed Web of Science ®Google Scholar
• Teva NeuroscienceCopaxone (glatiramer acetate) solution for subcutaneous injection [prescribing information]Overland Park (KS)Teva Neuroscience2012 Available from: http://copaxone.com/pdfs/PrescribingInformation.aspxAccessed May 12, 2014
   Google Scholar
• SellebjergFHedegaardCJKrakauerMGlatiramer acetate antibodies, gene expression and disease activity in multiple sclerosisMult Scler201218330531322020419
   PubMed Web of Science ®Google Scholar
• TeitelbaumDBrennerTAbramskyOAharoniRSelaMArnonRAntibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacyMult Scler20039659259914664472
   PubMed Web of Science ®Google Scholar
• BornsteinMBMillerASlagleSA pilot trial of Cop 1 in exacerbating-remitting multiple sclerosisN Engl J Med198731774084143302705
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJAExtended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study GroupNeurology19985037017089521260
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRFordCCGlatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trialMult Scler20039658559114664471
   PubMed Web of Science ®Google Scholar
• JohnsonKPFordCCLisakRPWolinskyJSGlatiramer acetate (Copaxone): neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year dataActa Neurol Scand20051111424715595937
   PubMed Web of Science ®Google Scholar
• FordCCJohnsonKPLisakRPA prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patientsMult Scler200612330932016764344
   PubMed Web of Science ®Google Scholar
• FordCGoodmanADJohnsonKContinuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMult Scler201016334235020106943
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMWolinskyJSEuropean/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosisAnn Neurol200149329029711261502
   PubMed Web of Science ®Google Scholar
• WolinskyJSComiGFilippiMCopaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustainedNeurology20025981284128612391370
   PubMed Web of Science ®Google Scholar
• RovarisMComiGRoccaMALong-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trialMult Scler200713450250817483532
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol200871090391418789766
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonB250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol200981088989719729344
   PubMed Web of Science ®Google Scholar
• CadavidDWolanskyLJSkurnickJEfficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME studyNeurology200972231976198319279320
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar
• FilippiMRovarisMRoccaMASormaniMPWolinskyJSComiGGlatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”Neurology200157473173311524494
   PubMed Web of Science ®Google Scholar
• CadavidDCheriyanJSkurnickJLincolnJAWolanskyLJCookSDNew acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetateJ Neurol Neurosurg Psychiatry200980121337134319687024
   PubMed Web of Science ®Google Scholar
• FilippiMRoccaMACamesascaFInterferon β-1b and glatiramer acetate effects on permanent black hole evolutionNeurology201176141222122821464426
   PubMed Web of Science ®Google Scholar
• GeYGrossmanRIUdupaJKGlatiramer acetate (Copaxone) treatment in relapsing–remitting MS: quantitative MR assessmentNeurology200054481381710690968
   PubMed Web of Science ®Google Scholar
• ArnoldDLNarayananSAntelSNeuroprotection with glatiramer acetate: evidence from the PreCISe trialJ Neurol201326071901190623589190
   PubMed Web of Science ®Google Scholar
• TeitelbaumDArnonRSelaMImmunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1Proc Natl Acad Sci U S A19999673842384710097125
   PubMed Web of Science ®Google Scholar
• CohenJARovarisMGoodmanADLadkaniDWynnDFilippiMRandomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MSNeurology2007681293994417372130
   PubMed Web of Science ®Google Scholar
• ComiGCohenJAArnoldDLWynnDFilippiMPhase III dose-comparison study of glatiramer acetate for multiple sclerosisAnn Neurol2011691758221280077
   PubMed Web of Science ®Google Scholar
• KhanOCaonCZakIRandomized, prospective, rater-blinded, four-year, pilot study to compare the effect of daily versus every-other-day glatiramer acetate 20 mg subcutaneous injections in relapsing–remitting multiple sclerosisMult Scler200814Suppl 1S296
   Google Scholar
• KhanOPerumalJCaonCGlatiramer acetate 20 mg subcutaneous twice-weekly versus daily injections: results of a pilot, prospective, randomized, and rater-blinded clinical and MRI 2-year study in relapsing–remitting multiple sclerosisMult Scler200915Suppl 2S249S250
   Google Scholar
• KhanORieckmannPBoykoASelmajKZivadinovRThree times weekly glatiramer acetate in relapsing–remitting multiple sclerosisAnn Neurol201373670571323686821
   PubMed Web of Science ®Google Scholar
• BosterABartoszekMPO’ConnellCPittDRackeMEfficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosisTher Adv Neurol Disord20114531933222010043
   PubMedGoogle Scholar
• JollyHSimpsonKBishopBImpact of warm compresses on local injection-site reactions with self-administered glatiramer acetateJ Neurosci Nurs200840423223918727339
   PubMed Web of Science ®Google Scholar
• Teva PharmaceuticalsCopaxone [package insert]Kfar Saba, IsraelTeva Pharmaceuticals2007
   Google Scholar
• Teva NeuroscienceCopaxone [package insert]Kansas City (MO)Teva Neuroscience2009
   Google Scholar
• HoutchensMKKolbCMMultiple sclerosis and pregnancy: therapeutic considerationsJ Neurol201326051202121422926165
   PubMed Web of Science ®Google Scholar
• CoylePJohnsonKPardoLPregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone)Poster presented at: 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)September 17–20, 2003Milan, Italy
   Google Scholar
• VenturaSJCurtinSCAbmaJCHenshawSKEstimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990–2008Nat Vital Stat Rep2012607121
   PubMedGoogle Scholar
• FragosoYDFinkelsztejnAKaimen-MacielDRLong-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case seriesCNS Drugs2010241196997620806993
   PubMed Web of Science ®Google Scholar
• SalminenHJLeggettHBoggildMGlatiramer acetate exposure in pregnancy: preliminary safety and birth outcomesJ Neurol2010257122020202320625758
   PubMed Web of Science ®Google Scholar
• HellwigKGoldRGlatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosisJ Neurol2011258350250320878174
   PubMed Web of Science ®Google Scholar
• HaleTWMedications and Mothers’ Milk14th edPlano (TX)Hale2010
   Google Scholar
• CostelloKKennedyPScanzilloJRecognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long termMedscape J Med200810922519008986
   PubMedGoogle Scholar
• DevonshireVLapierreYMacdonellRThe Global Adherence Project (GAP) – a multicenter observational study on adherence to disease-modifying therapies in patients suffering from relapsing–remitting multiple sclerosisPoster presented at: 22nd Congress of the European Committee for Treatment and Research in Multiple SclerosisSeptember 27–30, 2006Madrid, Spain
   Google Scholar
• HaasJFirzlaffMTwenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)Eur J Neurol200512642543115885045
   PubMed Web of Science ®Google Scholar
• MenzinJCaonCNicholsCWhiteLAFriedmanMPillMWNarrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosisJ Manag Care Pharm2013191 Suppl AS24S4023383731
   PubMed Web of Science ®Google Scholar
• SchrempfWZiemssenTGlatiramer acetate: mechanisms of action in multiple sclerosisAutoimmun Rev20076746947517643935
   PubMed Web of Science ®Google Scholar